VAN VOORHEES SETH
Known title: CHIEF FINANCIAL OFFICERCIK: 0001284934
VAN VOORHEES SETH's purchase track record
VAN VOORHEES SETH has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/16/2022 | NRXP | $33K | -38.3% | -54.8% | +14.5% |
| 11/25/2022 | NRXP | $18K | -13.0% | -39.1% | +4.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NRXP | ▲ Buy | Open Market | 30,000 | $33K | 12/16/2022 | View on chart |
| NRXP | ▲ Buy | Open Market | 8,716 | $10K | 11/25/2022 | View on chart |
| NRXP | ▲ Buy | Open Market | 600 | $660 | 11/25/2022 | View on chart |
| NRXP | ▲ Buy | Open Market | 7,021 | $8K | 11/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership
Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership. Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.